Cisplatin

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Retrieved on: 
Donnerstag, September 7, 2023
US Foods, Intensity, Vinblastine, Marketing, Survival, STS, Cisplatin, Trial of the century, SHAO, ASCO, Sarcoma, Orphan drug, Johns Hopkins University, Patient, Cancer, FDA, Therapy, Food, Pharmaceutical industry

"The designation of cisplatin, vinblastine and our diffusion enhancer, SHAO for orphan status for STS is quite important," said Lewis H. Bender President and CEO.

Key Points: 
  • "The designation of cisplatin, vinblastine and our diffusion enhancer, SHAO for orphan status for STS is quite important," said Lewis H. Bender President and CEO.
  • An FDA condition to obtain orphan drug designation was for the Company to provide a scientific rationale in its application with sufficient data to establish a medically plausible basis for expecting the drug to be effective in STS.
  • The Company submitted clinical data including immune activation results in sarcoma patients.
  • Data also reported at ASCO showed that INT230-6 when delivered locally led to a systemic immune response in several sarcoma subtypes that are considered to be non-immunogenic cancers.

Vizient: Lack of Information Across Supply Chain Exacerbating Oncology Drug Shortage

Retrieved on: 
Mittwoch, August 23, 2023
Practice Management, Pharmaceutical, Medical Supplies, Oncology, Health, Hospitals, Supply Chain Management, Retail, Docetaxel, Methotrexate, Cisplatin, Pharmacy, Carboplatin, Trust, Hospital, Patient, Cancer, Fluorouracil, Nursing

A Vizient white paper released today demonstrates how the lack of information about medication access across the supply chain is exacerbating the shortage of seven oncology drugs used to treat a multitude of cancers.

Key Points: 
  • A Vizient white paper released today demonstrates how the lack of information about medication access across the supply chain is exacerbating the shortage of seven oncology drugs used to treat a multitude of cancers.
  • View “Evaluating the impact of the oncology drug shortage.”
    Six antineoplastic oncology medications are in short supply in the United States due to the December shutdown of a manufacturing plant in India — capecitabine, carboplatin, cisplatin, docetaxel, fluorouracil and methotrexate; a seventh, fludarabine, has been in short supply since 2019.
  • “The fulfillment data we reviewed highlights challenges with how product availability and demand fluctuate considerably when a shortage occurs.
  • In April, Vizient conducted a survey of its pharmacy program participants with 32 unique oncology network provider customers responding.

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Montag, August 14, 2023
Workforce, Pancreatic cancer, SBRT, HNC, Therapy, Symantec Endpoint Protection, LAPC, Head, Glomerular filtration rate, Clinical trial, Survival, NDA, Cancer, New Drug Application, NSCLC, Cisplatin, ASCO, SOM, Radiation, GRECO, Patient, Investment, Annual general meeting, CRL, Research, FDA, Galera, CKD, Society, Food, Safety, Pharmaceutical industry

MALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.

Key Points: 
  • MALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.
  • Research and development expenses were $7.6 million in the second quarter of 2023, compared to $6.6 million for the same period in 2022.
  • General and administrative expenses were $9.2 million in the second quarter of 2023, compared to $5.3 million for the same period in 2022.
  • As of June 30, 2023, Galera had cash, cash equivalents and short-term investments of $38.8 million.

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Freitag, August 11, 2023
European Medicines Agency, CVR, Ear, Hearing loss, Regeneron Pharmaceuticals, Congenital hearing loss, COMP, Cancer, STS, Brain, Research, Cisplatin, AAV, Sale, Committee, EMA, Development, State Administrative Expenses, GJB2, Acquisition, Ototoxicity, Patient, Administration, Hearing, Orphan, Genetic distance, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Decibel

BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • In May 2023, Decibel announced the initiation of CHORD, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients.
  • Second Quarter 2023 Financial Results:
    Cash Position: As of June 30, 2023, cash, cash equivalents and available-for-sale securities were $78.3 million, compared to $104.6 million as of December 31, 2022.
  • Research and Development Expenses: Research and development expenses were $12.8 million for the second quarter of 2023, compared to $11.2 million for the same period in 2022.
  • General and Administrative Expenses: General and administrative expenses were $6.2 million for the second quarter of 2023, compared to $5.9 million for the same period in 2022.

Clinigen divests global rights to four cancer support therapies to CNX Therapeutics

Retrieved on: 
Donnerstag, August 10, 2023
Pharmaceutical Services Negotiating Committee, Heart, Laboratory, Radiation, Cancer, Greenhill & Co., Woman, Head, Cisplatin, Sale, Iovance Biotherapeutics, CNX, Patient, Drug Safety, Doxorubicin, Cardiomyopathy, Anthracycline, Therapy, Pharmaceutical industry, Fine chemical

Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.

Key Points: 
  • Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.
  • Cardioxane®, used in adults with advanced or metastatic breast cancer to prevent long-term harmful effects on the heart caused by treatment with certain anthracyclines.
  • Savene®, used to treat anthracycline extravasation in adults, a rare condition that can impact cancer patients.
  • Totect®, used for the treatment of anthracycline extravasation as well as for preventing cardiomyopathy associated with doxorubicin in women with metastatic breast cancer.

New Journal of Pharmaceutical Analysis Articles Showcase Promising Therapeutic Candidates for Treating Cancer and Hearing Loss

Retrieved on: 
Mittwoch, August 9, 2023
Neuron, DNA, Non-small-cell lung cancer, Hearing loss, JPA, XPO1, Cancer, Quality of life, Research, NSCLC, Cisplatin, Liver, DNA repair, HIV disease progression rates, Patient, Apoptosis, Cell cycle, METTL3, Dick's Picks Volume 13, Ataxia–telangiectasia, Leukemia, Kinetics, ATR, PRMT5, Pharmaceutical industry

XI'AN, China, Aug. 9, 2023 /PRNewswire/ -- Although cancer treatment has advanced significantly over the last decade, some fairly common cancers remain extremely difficult to treat. Besides, some chemotherapeutics or anti-cancer drugs can have serious, irreversible side-effects. The latest issue of the JPA features three articles that highlight novel treatment strategies based on cutting-edge research on cancer and chemotherapeutic drug-induced adverse events.

Key Points: 
  • The latest issue of the JPA features three articles that highlight novel treatment strategies based on cutting-edge research on cancer and chemotherapeutic drug-induced adverse events.
  • The first study reports a new approach to prevent hearing loss induced by the widely used chemotherapeutic drug "cisplatin".
  • The article was available online in April 2023 and published in Volume 13, Issue 6 in June 2023 .
  • A better understanding of the role of PRMT5 in hearing loss could help scientists develop effective hearing protection drugs and prevent this unwanted side-effect.

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, August 3, 2023
Bevacizumab, Radiation, CRC, Skin, Roche, Clinical trial, Merkel-cell carcinoma, SCCHN, Data collection, Uveal melanoma, RP3, Incyte, SOC, Cisplatin, RP1, ASCO, ORR, CSCC, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Standard of care, Melanoma, Carcinoma, CPS, Annual general meeting, Liver, Nivolumab, ATC, RP2, Kinetics, BLA, PD-L1, Society, Safety, Fatigue, Pharmaceutical industry, Vaccine, Medical imaging, Nursing

“It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.

Key Points: 
  • “It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.
  • S,G&A Expenses: Selling, general and administrative expenses were $15.2 million for the first quarter ended June 30, 2023, as compared to $11.4 million for the first quarter ended June 30, 2022.
  • Selling, general and administrative expenses included $5.5 million in stock-based compensation expenses for the first quarter ended June 30, 2023.
  • Net Loss: Net loss was $49.6 million for the first quarter ended June 30, 2023, as compared to a net loss of $42.3 million for the first quarter ended June 30, 2022.

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, August 3, 2023
Calendar, PTC Therapeutics, International, Hearing loss, Marketing, Bank statement, PTC, Cancer, Research, Cisplatin, Sale, RESEARCH, PIN, FENC, Patient, Administration, Webcast, TSX, Growth, Research and development, R, Therapy, Remuneration, Heads Up International, Conference, News, PARK, Software, Pharmaceutical industry, Gentium, G&A, Fennec

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2023 and provided a business update.
  • These results reflect strong growth in patient starts and new account orders,” said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals.
  • Selling and marketing expenses for the second quarter of 2023 were $2.3 million compared to $2.5 million in the first quarter of 2023.
  • ET, to discuss the Company’s financial results from the second quarter, ended June 30, 2023, and provide a business outlook for the remainder of 2023.

Team from Korea University Medicine Explores Ways to Overcome Cisplatin Resistance and Alleviate Pain in Cancer Treatment

Retrieved on: 
Freitag, Juli 21, 2023
Neoplasm, NANOG, Nature Communications, TRPV1, Epidermal growth factor, Cisplatin, EGF, Transcriptome, Drug resistance, Cervical cancer, Patient, EGFR, Neuropathic pain, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Metastasis, Platinum, Vaccine

SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented.

Key Points: 
  • However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.
  • But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain.
  • Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance.
  • This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer.

Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again

Retrieved on: 
Sonntag, Juli 2, 2023
Injection, Communication, Tablet, Gefitinib, Intelligence, FDA, Cisplatin, Lung cancer, Automation, Sale, Pharmaceutical industry

This is the second batch of drugs supplied by this well-known Chinese pharmaceutical company to the United States, following the first batch of 18000 cisplatin injections exported to the United States.

Key Points: 
  • This is the second batch of drugs supplied by this well-known Chinese pharmaceutical company to the United States, following the first batch of 18000 cisplatin injections exported to the United States.
  • On May 31st Beijing time, Qilu Pharmaceutical Group shipped 18000 bottles of cisplatin injection to the United States without affecting domestic product supply.
  • In addition, the FDA's rapid licensing of Qilu Pharmaceutical's cisplatin injection for export to the United States is related to the company's years of deep cultivation in the world's largest pharmaceutical market - the United States market.
  • With the shipment of cisplatin injection to the United States, this is already the 24th formulation product of Qilu Pharmaceutical Group to achieve commercial sales in the United States.